

From: [REDACTED]
To: [REDACTED]
Cc: [REDACTED]
Subject: [REDACTED] - letter dated 5 Jan 2021 - RE: Monash IVF investigation (DIR 65968) [SEC=OFFICIAL]
Date: Monday, 11 January 2021 12:01:14 PM
Attachments: [ID21-2029946](#) [REDACTED] - [Correspondence 5 Jan 2021.PDF](#)

Dear [REDACTED] & colleagues,

Just letting you know that the [REDACTED] sent a letter, dated 5 Jan 2021, requesting TGA inform them of the outcome of the investigation into Monash IVF's suspended pre-implantation genetic testing (DIR 65968). I will provide a response shortly to their letter.

A copy of the letter received 11 Jan 2021 has been scanned and is attached for your information ([D21-2029946](#))

Kind regards,

[REDACTED]

[REDACTED]
[REDACTED]

Devices Post Market Monitoring Section
Medical Devices Surveillance Branch

Phone: [REDACTED]

Email: [REDACTED]

Therapeutic Goods Administration
Department of Health
PO Box 100
Woden ACT 2606
www.tga.gov.au

For ongoing information and updates please subscribe to the TGA's [Medical Devices Information](#) and [IVDs Information](#) email subscription services.



This response is general information given to you without prejudice; it is not binding on the TGA and you should get your own independent legal advice to ensure that all of the legislative requirements are met.

Important: *This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission*